Novo Nordisk will pay all the research and development costs for the project. The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G ...

Novo Nordisk will pay all the research and development costs for the project. The US biotech company has developed a platform that finds and develops drugs that target special proteins called G ...

Septerna's partnership with Novo Nordisk validates ... the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale. This enables the company to apply the tools ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

The company said a search is "ongoing, and an announcement will be made in due course." Novo Nordisk cited "recent market challenges Novo Nordisk has been facing, and the development of the ...

The company said it would announce the next CEO in “due course,” but did not provide a more definite timeline. Jørgensen decided to step down as per a mutual agreement with the Novo Nordisk ...

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker, the top company in Europe by market cap. These medications, injected into the body, mimic a hormone that regulates blood ...

May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...

Novo Nordisk announced ... change was the “wish” of the Novo Nordisk Foundation, an independent nonprofit that controls the company—an ownership structure that is common among large Danish ...